Impact of Biological Effective Dose in Predicting Late Rectal Bleeding in Prostate Cancer
Author Information
Author(s): Christian A. M. Jongen, W. D. Heemsbergen, Luca Incrocci, Ben J. M. Heijmen, Linda Rossi
Primary Institution: Erasmus MC Cancer Institute, University Medical Center Rotterdam
Hypothesis
What is the added value of applying biological effective dose to dosiomic features in predicting late rectal bleeding after prostate cancer treatment?
Conclusion
Using the biological effective dose in predictive dosiomic modeling of late rectal bleeding after prostate cancer radiotherapy was of limited value.
Supporting Evidence
- Dosiomic features related to high doses were predictive for both hypofractionated and conventional fractionation.
- The models fitted to combined data showed better discriminative ability in conventional fractionation.
- The apparent performances of models for biological effective dose and physical dose were similar.
Takeaway
This study looked at how well a special dose calculation helps predict bleeding problems after prostate cancer treatment, and it found that it didn't help much.
Methodology
The study used data from 656 prostate cancer patients treated with either conventional or hypofractionated radiotherapy, extracting dosiomic features from their dose distributions and evaluating models for predicting late rectal bleeding.
Limitations
The models showed poor calibration when tested on data from the other fractionation scheme.
Participant Demographics
Intermediate- to high-risk prostate cancer patients treated in a randomized trial.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website